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ABSTRACT 29 
 30 
The vacuolating autotransporter (AT) toxin (Vat) contributes to Uropathogenic Escherichia coli 31 
(UPEC) fitness during systemic infection. Here we characterised Vat and investigated its 32 
regulation in UPEC. We assessed the prevalence of vat in a collection of 45 UPEC urosepsis 33 
strains and showed that it was present in 31 (68%) of the isolates. The isolates containing the vat 34 
gene corresponded to three major E. coli sequence types (ST12, 73 and 95) and these strains 35 
secreted the Vat protein. Further analysis of the vat genomic locus identified a conserved gene 36 
located directly downstream of vat that encodes a putative MarR-like transcriptional regulator, 37 
which we termed vatX. The vat-vatX genes were present in the UPEC reference strain CFT073 38 
and RT-PCR revealed both genes are co-transcribed. Over-expression of vatX in CFT073 led to a 39 
3-fold increase in vat gene transcription. The vat promoter region contained three putative 40 
nucleation sites for the global transcriptional regulator H-NS; thus the hns gene was mutated in 41 
CFT073 (to generate CFT073hns). Western blot analysis using a Vat-specific antibody revealed 42 
a significant increase in Vat expression in CFT073hns compared to wild-type CFT073. Direct H-43 
NS binding to the vat promoter region was demonstrated using purified H-NS in combination 44 
with electrophoresis mobility shift assays. Finally, Vat-specific antibodies were detected in 45 
plasma samples from urosepsis patients infected by vat-containing UPEC strains, demonstrating 46 
Vat is expressed during infection. Overall, this study has demonstrated that Vat is a highly 47 
prevalent and tightly regulated immunogenic SPATE secreted by UPEC during infection.  48 
 49 
IMPORTANCE  50 
 51 
Uropathogenic Escherichia coli (UPEC) are the major cause of hospital and community acquired 52 
urinary tract infections. The Vacuolating autotransporter toxin (Vat) is a cytotoxin known to 53 
contribute to UPEC fitness during murine sepsis infection. In this study, Vat was found to be 54 
highly conserved and prevalent among a collection of urosepsis clinical isolates, and expressed at 55 
human core body temperature. Regulation of vat was demonstrated to be directly repressed by 56 
the global transcriptional regulator H-NS and upregulated by the downstream gene vatX (a new 57 
MarR-type transcriptional regulator). Additionally, increased Vat-specific IgG titres were 58 
detected in plasma from corresponding urosepsis patients infected with vat-positive isolates. 59 
Hence, Vat is a highly conserved and tightly regulated urosepsis-associated virulence factor.60 
INTRODUCTION 61 
 62 
Urinary tract infections (UTIs) are one of the most common human infections, and affect 40-63 
50% of women and approximately 12% of men globally (1). UTIs are ascending infections and 64 
can involve infection of the bladder (cystitis), kidneys (pyelonephritis) or dissemination into the 65 
bloodstream (urosepsis). Uropathogenic Escherichia coli (UPEC) are the primary etiological 66 
agent of UTI and cause 70-90 % of all such infections (2). UPEC can survive in the urinary tract 67 
and cause disease due to a diverse range of virulence factors including fimbriae (3-6), 68 
autotransporter (AT) proteins (7-10), surface polysaccharides such as the O-antigen and capsule 69 
(11-13), iron acquisition systems (14-16) and toxins (17-21). 70 
 71 
AT proteins constitute a large family of proteins from Gram-negative bacteria that are 72 
translocated by a dedicated type V secretion system (reviewed in 22, 23-26). AT translocation 73 
also requires accessory proteins including the β-barrel assembly module (BAM) and the 74 
translocation and assembly module (TAM) (27-30). AT proteins consist of three major domains: 75 
(i) a signal peptide that targets the protein to the secretory apparatus for inner membrane 76 
translocation; (ii) a passenger domain that comprises the functional domain of the protein; and 77 
(iii) a translocator domain that inserts into the outer membrane (reviewed in 22, 23, 25, 31-33) . 78 
One major subgroup of AT proteins is the serine protease AT proteins of Enterobacteriaceae 79 
(SPATEs). SPATEs are characterised by the presence of an immunoglobulin A1-like protease 80 
domain (PF02395) within the passenger domain that contains the conserved serine protease motif 81 
GDSGS (34, 35). The first serine within this motif comprises the catalytic triad in conjunction 82 
with upstream conserved histidine and aspartate residues. SPATEs can be phylogenetically 83 
grouped into two classes (reviewed in 34, 36, 37). Class I SPATEs represent the major group of 84 
these proteins and exhibit cytotoxic activity (37-43). Class II SPATEs recognise a more diverse 85 
range of substrates including mucins (reviewed in 34, 36, 37) and immunomodulatory host 86 
proteins (44).  87 
 88 
The vacuolating AT toxin (Vat) of E. coli is a class II SPATE (34, 36, 45) that exhibits 89 
cytotoxicity to chicken embryonic fibroblast cells and contributes to avian cellulitis infection 90 
(46). The vat gene was originally identified within a pathogenicity island (Vat-PAI) from the 91 
avian pathogenic E. coli (APEC) strain Ec222 (46). The Vat-PAI is integrated into the Ec222 92 
chromosome at the thrW-tRNA site between the proA and yagU genes (45, 46). The Vat-PAI 93 
from Ec222 consists of 33 open reading frames (ORFs), with the vat gene residing at ORF#27. 94 
Only five additional ORFs in this PAI were reported to share homology with other previously 95 
known protein sequences. This includes the ORF located downstream of vat (ORF#26), which 96 
shares 44% amino acid identity to the P pilus associated transcriptional regulatory protein PapX 97 
from UPEC strain CFT073 (46). PapX belongs to the family of multiple antibiotic resistance 98 
(MarR) regulators of Enterobacteriaceae and contributes to flagella regulation by binding to the 99 
promoter region of the flhDC master regulator genes (47-49). In UPEC, the vat gene is 100 
associated with virulence and contributes to survival during murine systemic infection (50). 101 
 102 
The full-length Vat protein is ~140 kDa and is processed during translocation to release a 111.8 103 
kDa passenger domain into the extracellular milieu. Vat shares 78% identity to the APEC 104 
associated Temperature-sensitive hemagglutinin (Tsh), which is almost identical (99% amino 105 
acid identity) to the SPATE Haemoglobin binding protein (Hbp) (51, 52). Hbp has been analysed 106 
extensively in the E. coli intra-abdominal clinical strain EB1, and its crystal structure has been 107 
solved (53, 54). Tsh/Hbp possess dual proteolytic and adhesive properties (55-57). Unlike 108 
Tsh/Hbp, Vat is unable to digest casein at 37°C (45, 46).   109 
 110 
Despite these functional differences, the high protein sequence identity shared between Tsh/Hbp 111 
and Vat has led to confusion in the annotation of vat genes within E. coli genomes available on 112 
the NCBI database. For example, the CFT073 vat gene (c0393) has been annotated as hbp (58), 113 
and even referred to as tsh due to its temperature-dependent regulation (59). In addition, the vat 114 
gene from UPEC strain 536 is annotated as sepA, which encodes the Shigella extracellular 115 
protein A (45).  116 
 117 
In this study, we have examined the sequence conservation of vat genes from available E. coli 118 
genomes and compared its genomic location, with the aim to correct existing annotation errors 119 
and vat nomenclature. We also examined the role of the putative MarR regulator identified 120 
downstream of the vat gene as well as the histone-like nucleoid protein H-NS in regulation of the 121 
vat gene. Finally, we examined the prevalence, expression and secretion of Vat in a collection of 122 
UPEC urosepsis isolates, and investigated its immunogenicity by examining plasma from 123 
urosepsis patients.  124 
 125 
MATERIALS AND METHODS 126 
 127 
Ethics statement. This study was performed in accordance with the ethical standards of The 128 
University of Queensland, Princess Alexandra Hospital, Gold Coast Hospital, Queensland 129 
Health, Griffith University and the Helsinki Declaration. The study was approved, and the need 130 
for informed consent was waived by the institutional review boards of the Princess Alexandra 131 
Hospital (2008/264), Queensland Health and Griffith University (MSC/18/10/HREC). 132 
 133 
Bacterial strains and growth conditions. E. coli strains CFT073 (60), IHE3034 (61), 536 (62), 134 
MG1655 (63) and BL21 (64), as well as the E. coli reference (ECOR) collection (65), have been 135 
described previously. The 45 urosepsis UPEC strains were isolated from the blood of patients 136 
presenting with urosepsis at the Princess Alexandra Hospital (Brisbane, Australia). A matching 137 
urine sample was also cultured from each patient; in all cases the blood and urine isolates were 138 
identical as determined by virulence gene profiling. Unless otherwise stated, strains used in this 139 
study were routinely grown at 37°C on solid or in liquid Lysogeny broth (LB) supplemented 140 
with antibiotics: kanamycin (kan [100μg/mL]), ampicillin (amp [100μg/mL]) or chloramphenicol 141 
(cam [30μg/mL]). Supplementation of growth media with L-arabinose (0.2% [w/v]) or isopropyl 142 
β-D-1-thiogalactopyranoside (IPTG [1mM]) was used to induce plasmid-mediated gene 143 
expression. 144 
 145 
Bioinformatic analysis. The presence of the vat gene was determined in 77 complete E. coli 146 
genomes (listed in Table S1) available from the National Centre for Biotechnology Information 147 
(NCBI) database by BLAST analysis using the vat gene (c0393) from the CFT073 genome 148 
(Genbank accession no.: AE014075.1 (58)) as a search tool. The cut-off was set at >85% amino 149 
acid identity of the encoded protein sequence. The genomic location surrounding the vat gene in 150 
each of the vat-positive strains was investigated in Artemis (66). All vat genes identified were 151 
located on a PAI defined by the proA and yagU genes. The nucleotide sequence of each vat-152 
associated PAI was compared in EasyFig (67).  153 
A comparative protein analysis of the MarR family of transcriptional regulators (Table S2) was 154 
performed to analyse their relative phylogenetic relationship to VatX. The MarR dataset was 155 
compiled using an iterative approach that involved BLAST analysis against the 77 complete 156 
NCBI E. coli genomes listed in Table S1. Representative protein sequences, underlined in Table 157 
S2, were chosen for each MarR type regulator based on previous characterisation in the 158 
literature. These sequences included MarR from MG1655 (b1530), MprA(EmrR) from MG1655 159 
(b2684), HosA from E2348/69 (E2348C_3010), HpcR/ HpaR from strain W (WFL_22965), 160 
SlyA from MG1655 (b1642) and PapX from CFT073 (c3582). Each of the representative 161 
sequences were used to BLAST against the 77 complete E. coli genomes and 330 homologous 162 
protein sequences were identified (E<0.001). The evolutionary relationship between VatX and 163 
other representative MarR regulators, as well as the protein sequences listed in Table S2,  was 164 
inferred using ClustalΩ (68, 69) and visualised through FigTree (70).  165 
 166 
DNA manipulation and genetic techniques. DNA techniques were performed as previously 167 
described (71). Isolation of plasmid DNA was performed using the QIAprep spin column 168 
miniprep kit (QIAGEN). Polymerase chain reactions (PCR) were performed using the specified 169 
primers which were sourced from Integrated DNA Technologies (Singapore). PCR products 170 
were amplified using Taq DNA polymerase according to the manufacturer’s instructions (New 171 
England Biolabs). Sequencing reactions were performed using the BigDye Terminator v3.1 cycle 172 
DNA sequencing kit as per the manufacturer's specifications (Applied Biosystems) and analysed 173 
by the Australian Equine Genome Research Centre. Cloning reactions involving restriction 174 
endonucleases were performed as per the manufacturer’s instructions (New England Biolabs).  175 
 176 
Multi locus sequence typing (MLST) and PCR screening. Prevalence of the vat gene was 177 
assessed by PCR using primers 2020 (5’-GTATATGGGGGGCAACATAC-3’) and 2021 (5’-178 
GTGTCAGAACGGAATTGTCG-3’), which were designed based on the sequence of the vat 179 
gene from CFT073 (c0393). The vat gene sequence from ten of the 31 vat-positive UPEC 180 
urosepsis strains was determined and deposited on the NCBI database (accession numbers: 181 
PA11B vat, KR094926; PA15B vat, KR094927; PA32B vat, KR094928; PA38B vat, 182 
KR094929; PA42B vat, KR094930; PA48B vat, KR094931; PA56B vat, KR094932; PA57B 183 
vat, KR094933; PA60B vat, KR094934; PA66B vat, KR094935). The sequence type of the 184 
UPEC urosepsis strains was determined using the seven-gene MLST scheme 185 
(http://mlst.ucc.ie/mlst/dbs/Ecoli) (72). PCR was performed as follows: initial denaturation at 186 
94°C for 5 m; 25 cycles of denaturation at 94°C for 30 s, annealing at 50°C for 30 s, extension at 187 
72°C for 30 s followed by a final extension at 72°C for 7 m.  188 
 189 
Construction of deletion mutants. The vat (c0393), vatX (c0392) and hns (c1701) genes were 190 
mutated in CFT073 using λ-Red mediated homologous recombination (73). Briefly, the 191 
kanamycin gene from pKD4 or the chloramphenicol gene from pKD3 were amplified using PCR 192 
primers containing 50-bp flanking regions homologous to the target genes vat (3353: 5’-193 
TCGTAATGAACACAGTTCATCTGATCTCCACACACCAAGACTTGATAAGCTcacgtcttga194 
gcgattgtgtagg-3’ and 3354:  5’-195 
GAAACCACCACCCCATGATTTTGTTTTACCGCTGTACAGGCCTGCTGACGCgacatgggaa196 
ttagccatggtcc-3’), vatX (5232: 5’-197 
TTCACGATACTTCATGTAACACTCAGGTTGAGTAATCTTCgtgtaggctggagctgcttc-3’ and 198 
5233:  5’-199 
AGAATACATTGTAAGAAGATGACTGTTAGTATGTTTTAACAcatatgaatatcctcctta-3’) or 200 
hns (1583: 5’-201 
TCGTGCGCAGGCAAGAGAATGTACACTTGAAACGCTGGAAGAAATGCTGGgtgtaggctg202 
gagctgcttc-3’ and 1584: 5’-203 
TTGATTACAGCTGGAGTACGGCCCTGGCCAGTCCAGGTTTTAGTTTCGCCcatatgaatatcc204 
tccttag-3’). Amplified fragments were transformed into CFT073(pKD56) expressing of the λ-205 
Red recombinase in order to facilitate homologous recombination for inactivation deletion of the 206 
target gene. Removal of the antibiotic resistance gene cassette was performed using plasmid 207 
pCP20 as previously described, and enabled the construction of the CFT073vatX hns double 208 
mutant. 209 
 210 
Construction of plasmids. A segment of the vat gene corresponding to amino acid residues 63-211 
465 of the passenger domain was amplified from CFT073 using primers 1491 (5’-212 
tacttccaatccaatgcTCCTTACCAGACATACCGCG-3’) and 1494 (5’-213 
ttatccacttccaatgTTACCCCGCATATTGATCATTGCC-3’) and cloned as a 6 x histidine N-214 
terminal fusion into the pLicA vector using ligation independent cloning (designated pVat403). 215 
The full-length vat gene (c0393) and the downstream gene vatX gene (c0392) were PCR 216 
amplified from CFT073 using the following primer pairs; vat: 1524 (5’-217 
cgcgCTCGAGataataaggaattactATGAATAAAATATACGCTC-3’) and 1525 (5’-218 
cgcgcaagcttCAAAGCAATAGTCCCTTTGC-3’); and vatX: 5244 (5’-219 
cgcgctcgagataataaggaaTCTTCATGAGTTTTCTTTTGCCGTGTGG-3’) and 5245 (5’-220 
cccggaagcttTCAATTAACATTAAGGTTTGATA-3’). The PCR products were purified and 221 
cloned into XhoI-HindIII digested pSU2718 to generate the plasmids pVat and pVatX. 222 
Transcription of the vat and vatX genes in these plasmids was regulated by the lac promoter (74).  223 
 224 
Comparative quantitative reverse transcriptase PCR (qRT-PCR). Comparative qRT-PCR 225 
was performed essentially as previously described (47). Briefly, strains CFT073, CFT073vatX 226 
and CFT073vatX (pVatX) were grown in LB broth (supplemented with IPTG) until exponential 227 
growth phase. The total RNA from each strain was extracted using the RNeasy mini kit as per 228 
manufacturer’s instructions (QIAGEN). Samples were subjected to RNase free DNA digestion 229 
and first strand cDNA synthesis was performed using SuperscriptIII (Invitrogen Life 230 
Technologies) with random hexamer (50ng/μL) primers (Invitrogen Life Technologies). 231 
Residual RNA was digested by RNaseH and samples were re-purified as recommended by the 232 
manufacturer (QIAGEN). The ViiA 7 instrument and software (v 1.2.1) was used to carry out RT 233 
PCR reactions (95°C 10 s; 95°C 15 s, 60°C 15 s and 72°C 30 s for 40 cycles). Primers specific to 234 
the vat gene (5470: 5’-TACCGTAACCAGCTCATCAACAG-3’ and 5471: 5’- 235 
CATACCCACCTGTTACCCAATGT-3’) and gapA (control; 820: 5’-236 
GGTGCGAAGAAAGTGGTTATGAC-3’ and 821: 5’-GGCCAGCATATTTGTCGAAGTTAG-237 
3’) were used to amplify transcripts with SybrGreenI (5 μL) master mix (Applied Biosystems). 238 
Each reaction was performed in triplicate and a subsequent melt curve was generated for 239 
validation of the results (95°C 15 s, 60°C 1 m and 95°C for 10 s). Cycle threshold values 240 
obtained were normalised to the endogenous control and the 2-∆∆Ct method (75) was applied for 241 
the comparative analysis. The resulting ratios were statistically analysed using a one-way 242 
ANOVA. All experiments were performed in triplicate. 243 
 244 
5' RACE and Virtual Footprint analysis. The transcriptional start site for vat was determined 245 
using the 5' RACE system for rapid amplification of cDNA ends (version 2.0, Invitrogen Life 246 
Technologies) following the manufacture’s specifications. Two gene specific primers (5863: 5’-247 
ATGCAGATAGTGCCAGAG-3’ and 5864: 5’-CTCTGCGGGTACTCCCTTTAC-3’) were 248 
used. Putative DNA binding motifs in the vat promoter region were identified using Virtual 249 
Footprint software (76). 250 
 251 
Electrophoretic mobility shift assay (EMSA). EMSA was performed essentially as described 252 
previously (77) but with minor adaptations. Briefly, four individual fragments (152 bp, 218 bp, 253 
312 bp and 479 bp) were PCR amplified from the plasmid pBR322 (152 bp: 5’-254 
CATTGGACCGCTGATCGT-3’ and 5’-CTTCCATTCAGGTCGAGGT-3’; 218 bp: 5’-255 
AATATTATTGAAGCATTTATCAGGGTTA-3’ and 5’-256 
ATGATAAGCTGTCAAACATGAGA-3’; 312 bp: 5’-TATCGACTACGCGATCATGG-3’ and 257 
5’-TCTCCCTTATGCGACTCCTG-3’; and 479 bp: 5’-GACCGATGCCCTTGAGAG-3’ and 5’-258 
GATCGAAGTTAGGCTGGTAAGA-3’). The 218-bp fragment containing the H-NS repressed 259 
bla gene promoter was included in the assay as a positive control, while the remaining three 260 
fragments do not bind H-NS. The vat gene promoter region (252 bp) encompassing all three of 261 
the putative H-NS binding sites identified, was also PCR amplified (6103: 5’-262 
CCTGAGAAAAAGCAAACAACA-3’ and 6104: 5’-TTTTAGAGCGTATATTTTATTCAT-3’) 263 
from the genomic DNA of CFT073. This 252-bp fragment was added in an equimolar ratio with 264 
the control fragments (7.5 nM per fragment [~100 ng]). Purified native H-NS protein was added 265 
to each reaction in increasing concentrations (0 μM, 0.1 μM, 0.5 μM and 1.0 μM). Reactions 266 
were incubated at room temperature (15 m in H-NS binding buffer to allow for protein-DNA 267 
complex formation. Samples were examined by high-resolution agarose gel electrophoresis (3% 268 
Lonza Metaphor [50 V at 4°C]), and viewed under ultraviolet light after staining with ethidium 269 
bromide (0.5μg/ mL). Invitrogen’s 1 kbp+ ladder was used as a molecular marker. 270 
 271 
Preparation of supernatant proteins. Bacterial cultures (10 mL) were standardised to an 272 
optical density at 600nm equal to 1.0 (OD600 = 1.0), centrifuged (2057 x g), and the supernatant 273 
was collected and filtered (0.22 µm). Proteins were precipitated by the addition of 10% 274 
trichloroacetic acid (TCA) overnight at 4°C. Following precipitation, supernatant fractions were 275 
concentrated by centrifugation (12,100 x g) and washed twice with 80% acetone to remove 276 
residual TCA. Proteins were resuspended in a final volume of 0.1 mL (100-fold concentration). 277 
 278 
Purification of denatured His-tagged Vat protein. A bacterial culture (200mL) of E. coli 279 
BL21 λDE3 expressing the truncated Vat403 protein encoded on plasmid pVat403 was grown in 280 
LB. Bacterial cells were pelleted by centrifugation (2057 x g) and lysed (7M urea, 0.1 M 281 
NaH2PO4, 0.01 M Tris·Cl [pH 8.0]). The recombinant Vat403 protein was purified under 282 
denaturing conditions using QIAGEN’s Ni-NTA spin column kit. The cleared lysate was passed 283 
through a pre-equilibrated column via centrifugation (270 x g) to allow for the 6xHis tagged-Vat 284 
protein to bind. The column was washed (0.1 M NaH2PO4, 0.01 M Tris·Cl ([pH 6.3]) and the 285 
bound Vat protein was eluted (0.1 M NaH2PO4, 0.01 M Tris·Cl [pH 4.5]) by centrifugation (890 286 
x g). Protein concentrations were determined using the bicinchoninic acid protein assay kit as per 287 
the manufacturer’s instructions (Thermo Scientific Pierce Biotechnology). Purity of the eluted 288 
protein was validated by sodium-dodecyl-disulfide polyacrylamide gel electrophoresis (SDS-289 
PAGE) analysis (12% polyacrylamide gel) and Coomassie staining. 290 
 291 
Immunoblotting. The purified His-tagged recombinant Vat protein was used to generate a Vat-292 
specific polyclonal antibody following a standard protocol (Institute of Medical and Veterinary 293 
Science, South Australia). Concentrated supernatant proteins were re-suspended in 50 µL of SDS 294 
loading buffer (100 mM Tris-HCl, 4% w/v SDS, 20% w/v glycerol, 0.2% w/v bromophenol blue, 295 
pH 6.8) and a 10 µL sample was boiled for 10 min prior to SDS-PAGE. SDS-PAGE and transfer 296 
of proteins to a PVDF membrane for western blot analysis was performed as previously 297 
described (78). Anti-Vat polyclonal antibodies were used as the primary antibody, and alkaline 298 
phosphatase conjugated anti-rabbit antibodies (Sigma Aldrich) were used as the secondary 299 
antibody. SIGMAFASTTM BCIP®/NBT (Sigma-Aldrich) was used as the substrate for detection. 300 
 301 
Human plasma samples and measurement of Vat immunogenicity. Blood plasma (collected 302 
within 4 days post-admission) and matching clinical isolates were obtained from 45 urosepsis 303 
patients admitted to the Princess Alexandra Hospital (Brisbane, Australia).  The clinical strains 304 
isolated from each urosepsis patient were grouped as Vat positive (Vat+) and Vat-negative (Vat-) 305 
according to the prevalence of the vat gene, as determined by PCR screening using vat specific 306 
primers. A negative control group of plasma samples was independently obtained from 42 307 
healthy volunteers with no recent history of UTI. The ELISA assay was performed using Nunc 308 
MaxiSorp flat-bottom 96 well microtiter plates (Thermo Scientific). Each well was coated with 309 
recombinant Vat protein (10 µg/ml) using carbonate coating buffer (18 mM Na2CO3, 450 mM 310 
NaHCO3, pH 9.3 [4°C, overnight]). Plates were washed twice with 0.05% v/v Tween20 PBS 311 
(PBST) and blocked with 5% w/v skim milk in PBST (150 µl) for 90 min at 37°C. Each well 312 
was then washed four times with PBST prior to incubation (90 min at 37°C) with individual 313 
plasma samples (1:10 dilution). Unbound antibodies were removed by washing with PBST. 314 
Peroxidase-conjugated anti-human IgG (1:30,000 dilution in 5% skim milk) was applied as a 315 
secondary antibody for detection (incubated at 37°C for 90 min). Plates were washed four times 316 
with PBST and bound anti-human IgG was detected using 3,3',5,5'-tetramethylbenzidine as a 317 
substrate. Reactions were stopped with 1 M HCl. The absorbance of each well was measured at 318 
450 nm using the Spectramax plus384 plate reader via the SoftMax Pro®v5 program. Data 319 
obtained was analysed using GraphPrism5 software and a one-way ANOVA statistical analysis 320 
was performed. 321 
 322 
RESULTS 323 
 324 
The vat gene is located on a pathogenicity island at a conserved genomic location. The 325 
prevalence of vat was assessed in 77 complete E. coli genomes available on the NCBI database 326 
(Table S1). The vat gene was identified in 14 of these strains; these included the previously 327 
characterised vat-positive UPEC strains CFT073 and 536, as well as twelve additional strains 328 
from which vat has not previously been characterised (APEC O1, NRG 857C, LF82, IHE3034, 329 
S88, 83972, PMV-1, clone D i2, clone D i14, ATCC 25922, Nissle 1917 and UM146). In all 12 330 
strains, the vat gene was part of a pathogenicity island (PAI) flanked by the proA and yagU 331 
genes relative to the E. coli K12 MG1655 chromosome. This genomic location is consistent with 332 
the original identification of vat in APEC strain Ec222 (46). Closer examination of the genomic 333 
context of vat revealed that the upstream region (i.e. the yagU end) is highly conserved. In 334 
contrast, the region downstream of vat (i.e. the proA end) exhibits extensive variation, with a 335 
range of different DNA segments inserted at various positions of the PAI in strains APEC 01, 336 
83972, UM146, 536 and Ec222 (Fig. 1A).  337 
 338 
Vat is secreted by several genome sequenced UPEC strains. The secretion of Vat following 339 
growth in LB broth at 37°C was assessed from a selection of the vat-positive UPEC strains 340 
described above (i.e. CFT073, IHE3034 and 536). As a positive control, the vat gene from 341 
CFT073 was amplified by PCR, cloned into the low copy number expression vector pSU2718 to 342 
generate the plasmid pVat, and transformed into E. coli MG1655 to generate the recombinant 343 
strain MG1655(pVat). Western blot analysis using a Vat-specific antibody detected a single band 344 
of ~110 kDa that corresponded to the predicted size of the secreted passenger domain of Vat in 345 
the supernatant of MG1655(pVat), but not the vector control strain MG1655(pSU2718) (Fig. 346 
1B). The vat gene was also mutated in CFT073 to generate null mutant strain CFT073vat. SDS-347 
PAGE and western blot analysis of the supernatant fraction obtained from CFT073 and 348 
CFT073vat using our Vat-specific antibody identified the secreted Vat passenger domain from 349 
CFT073 but not CFT073vat (Fig. 1B). Finally, we also detected bands corresponding to the Vat 350 
passenger domain in the supernatant fraction prepared from strains IHE3034 and 536. Taken 351 
together, our data demonstrate that Vat is expressed and secreted by the genome-sequenced 352 
strains CFT073, IHE3034 and 536.  353 
 354 
A marR-like gene is located immediately downstream of the vat gene. We were interested to 355 
study the regulation of Vat, and noted a small open reading frame located directly downstream of 356 
the vat gene in all vat-positive strains (Fig. 1A). This gene, which we have termed vatX, 357 
corresponds to c0392 in CFT073 (58) and ORF#26 in the Vat PAI from Ec222 (46). The VatX 358 
protein sequence is highly conserved (99% amino acid identity in the 14 vat-positive completely 359 
sequenced strains described above) and shares 44% amino acid identity with the CFT073 P pilus-360 
associated transcriptional regulator PapX. Further analysis of VatX revealed it contains a MarR 361 
PFAM domain (PF01047) and a helix-turn-helix motif characteristic of DNA binding proteins. 362 
To examine the relationship between VatX and other regulator proteins, we generated a dataset 363 
comprising previously characterised E. coli MarR type regulators (Table S2) (47, 79-82). A 364 
multiple sequence alignment using representative regulator protein sequences (Fig. 2) as well as 365 
a more detailed phylogenetic analysis of all MarR-like sequences identified in the 77 complete E. 366 
coli genomes described above (Fig S1) revealed that VatX forms a distinct clade within the 367 
MarR regulator family, and is most closely related to the PapX, SfaX and FocX fimbriae-368 
associated regulators (47, 80, 83, 84). 369 
 370 
Expression of the vat gene is upregulated by VatX. The proximity, orientation and conserved 371 
genetic organization of the vat and vatX genes led us to examine if VatX contributes to the 372 
regulation of the vat gene. In order to study this, we generated a CFT073 vatX mutant 373 
(CFT073vatX) and examined the transcription of vat in CFT073 and CFT073vatX using 374 
comparative qRT-PCR. In addition, the vatX gene from CFT073 was PCR amplified and cloned 375 
into the pSU2718 expression vector (to generate the plasmid pVatX) and used to complement the 376 
CFT073vatX mutant. No significant difference was observed in the level of vat mRNA 377 
transcribed in CFT073 and CFT073vatX following growth in LB broth at 37°C (Fig. 3A). 378 
However, the over-expression of VatX in CFT073vatX (pVatX) resulted in an approximately 3-379 
fold higher level of vat mRNA transcript compared to WT CFT073 (Fig. 3A). To explore the 380 
effect of VatX on Vat expression further, we compared the level of Vat secreted into the 381 
supernatant fraction by CFT073, CFT073vatX and CFT073vatX(pVatX) by western blot analysis 382 
(Fig 3B). Consistent with our transcriptional data, the over-expression of VatX in 383 
CFT073vatX(pVatX) resulted in a significantly increased level of Vat in the culture supernatant, 384 
while no difference in the level of secreted Vat was observed in CFT073 and CFT073vatX. A 385 
similar increase in secreted Vat was also observed when WT CFT073 was transformed with 386 
plasmid pVatX (i.e. strain CFT073[pVatX]) (Fig. 3B). Taken together, our results demonstrate 387 
that while deletion of vatX does not alter the level of Vat secretion, its over-expression 388 
significantly enhances Vat expression. 389 
 390 
Transcription of the vat gene is directly repressed by H-NS. Given the regulatory effect 391 
exhibited by VatX on vat transcription, we investigated the promoter region of the vat gene to 392 
identify putative binding sites for other transcription factors. The transcriptional start site for vat 393 
was determined using 5' RACE and was mapped to a position 80-bp upstream of the Vat ATG 394 
start codon. Consensus -35 (5’-ATCACA-3’) and -10 (5’-ATTAAT-3’) promoter sequence 395 
elements, separated by an 18-bp spacer region, were identified upstream of this site (Fig. 4A). 396 
Virtual footprint software was used to analyse the vat promoter region for putative regulatory 397 
binding sites. From this in silico analysis, two putative H-NS nucleation sites were identified on 398 
the anti-sense strand overlapping the 18-bp spacer region and the 5’ end of the -35 element. A 399 
third H-NS nucleation site was determined on the direct strand 10-bp downstream of the 400 
transcriptional start site. 401 
 402 
The global transcriptional regulator H-NS is known to bind to curved and A-T rich DNA 403 
sequences upstream of several defined UPEC virulence genes (85), including genes encoding for 404 
toxins (86-89) and autotransporter proteins (8, 10, 90). To investigate the effect of H-NS on vat 405 
transcription, the level of Vat expression was compared by western blot analysis of supernatant 406 
fractions prepared from WT CFT073, CFT073vat, CFT073vatX, CFT073hns and a CFT073vatX 407 
hns double mutant (Fig. 4B). The amount of Vat secreted by CFT073hns and CFT073vatX hns 408 
was markedly increased compared to WT CFT073. Consistent with previous results, the level of 409 
Vat detected in supernatant fraction of CFT073vatX was similar to that detected from WT 410 
CFT073.  411 
 412 
H-NS binds to the vat promoter region. To further investigate the role of H-NS in repression of 413 
vat transcription, an EMSA was performed using increasing concentrations of native H-NS 414 
protein and the 252bp PCR amplified region of the vat gene promoter possessing the three 415 
potential H-NS binding sites (Fig 4C). As a positive control, the bla gene promoter from the 416 
cloning vector pBR322 was also PCR amplified and included in the assay; H-NS is known to 417 
bind to this DNA fragment (91). Three additional fragments amplified from regions of pBR322 418 
known not to bind H-NS were included in the assay as negative controls. In our experiment, H-419 
NS bound with strong affinity to the DNA fragment corresponding to the vat gene promoter. 420 
Indeed, this binding affinity was stronger than that observed for the DNA fragment containing 421 
the control bla gene promoter. No binding of H-NS was observed to the negative control DNA 422 
fragments, demonstrating the specificity of H-NS binding in this assay.  423 
 424 
The vatX gene is co-transcribed with vat. H-NS regulates the transcription of several UPEC 425 
genes by competing for binding to their promoter element with a MarR-type regulatory protein; 426 
this includes SfaX binding to the sfaII fimbrial promoter (80), PapX binding to the flhDC flagella 427 
master regulator promoter (92), and SlyA binding to the type 1 fimbriae fimB recombinase 428 
promoter (93). The SfaX and PapX regulators are co-transcribed as part of their respective 429 
upstream fimbrial operon (encoding S and P type fimbriae, respectively (47, 80)). Taking this 430 
into consideration, we employed RT-PCR analysis to test for transcription of the vat and vatX 431 
genes as a single mRNA in CFT073. Due to the increased amount of Vat protein secreted by the 432 
CFT073hns mutant strain (as shown by Western blot analysis), total RNA was extracted from 433 
this strain, converted to cDNA and screened for a vat-vatX nucleic acid fragment using internal 434 
primers specific for both genes by RT-PCR (Fig. 4D). For comparison, an additional set of 435 
primers were used to amplify the vatX gene alone. Bands corresponding to the predicted sizes 436 
determined for the vatX and the vat-vatX transcripts were amplified from CFT073hns cDNA. 437 
Thus, while we cannot rule out the presence of an independent promoter upstream of vatX, our 438 
results demonstrate that the vat-vatX genes are co-transcribed in the absence of H-NS.  439 
 440 
Vat is prevalent, highly conserved and is secreted by UPEC urosepsis isolates. The vat gene 441 
has previously been shown to be most prevalent in E. coli strains from the B2 phylogenetic 442 
group, with a similar distribution observed among cystitis, pyelonephritis, prostatitis and 443 
bloodstream isolates (45). Based on the observation that vat is required for UPEC fitness in a 444 
mouse model of systemic infection (50), we screened a collection of urosepsis strains for the vat 445 
gene by PCR. The vat gene was identified in 68% (31/45) of the urosepsis strains. MLST 446 
analysis revealed strains from ST73, ST12 and ST95 were most predominant in this collection 447 
(Fig. 5). Furthermore, supernatant fractions produced by these strains were examined by Western 448 
blotting to analyse the expression and secretion of Vat following growth in LB at 37°C. For all 449 
strains, a band corresponding to the Vat passenger domain hybridised with the Vat-specific 450 
polyclonal antibody. The sequence of the vat gene was determined from vat-positive strains 451 
representing each ST and found to be highly conserved (≥97% amino acid identity [Fig. 5]). 452 
Minor sequence variations occurred at six locations within the passenger domain of the protein. 453 
These residues were located within two regions in the Vat passenger domain (Fig. 5), both of 454 
which are distal to the serine protease catalytic motif based on a structural model built using the 455 
Hbp passenger domain (Fig. S2).  456 
 457 
The presence of vat is associated with increased anti-Vat IgG produced during infection. 458 
The high prevalence of vat in the UPEC urosepsis strains examined in this study, in combination 459 
with its secretion during in vitro growth, prompted us to examine if an immunological response 460 
against Vat was elicited during infection. To test this, an ELISA assay was performed using 461 
blood plasma samples collected from the same urosepsis patients from which the urosepsis 462 
strains were collected (Fig. 6). The blood plasma samples were examined for the presence of 463 
Vat-specific IgG antibodies using purified recombinant Vat protein. The urosepsis patients were 464 
divided into two groups; those infected with a vat-positive UPEC strain (n=31) and those 465 
infected with a vat-negative UPEC strain (n=14). As an additional control, 42 plasma samples 466 
collected from age and sex matched healthy individuals were also examined for an 467 
immunological response against the Vat protein. In this assay, we observed a significant 468 
difference (P < 0.05) in the anti-Vat IgG plasma titre in patients infected with a vat-positive 469 
strain compared to a vat-negative strain or healthy individuals. Taken together, these data 470 
suggest that Vat is a highly conserved immunogenic protein that is expressed by many UPEC 471 
isolates during infection.   472 
 473 
DISCUSSION  474 
 475 
UPEC strains possess an array of virulence factors that are critical for their ability to cause 476 
disease in extra-intestinal niches such as the urinary tract and the bloodstream (94, 95). Vat is a 477 
member of the SPATEs that contributes to fitness of E. coli during systemic infection (46, 50). In 478 
this study, we performed a comprehensive bioinformatic and molecular analysis of the vat gene. 479 
We defined the transcriptional regulation of vat and demonstrated its immunogenicity using 480 
plasma samples from urosepsis patients. 481 
 482 
The genomic location of the vat gene was examined in all vat-positive completely sequenced E. 483 
coli strains available on the NCBI database. The vat gene was shown to reside within the thrW-484 
PAI, downstream of proA and upstream of yagU relative to the E. coli MG1655 chromosome. 485 
This is consistent with a previous report that examined the presence of vat in UPEC strains 486 
CFT073 and 536, as well as the neonatal meningitis strain RS218 (45). The gene content of the 487 
vat-containing thrW-PAI was conserved in the majority of strains examined, although some 488 
differences were noted in strains Ec222, APEC-O1, 83972, UM146 and 536. Overall, our 489 
bioinformatic analysis revealed that the vat gene (and the co-located vatX regulator gene) is 490 
present in a range of different E. coli pathoypes.  491 
 492 
Several studies have previously assessed the prevalence of the vat gene in E. coli. A study 493 
conducted by Parham et al (45) reported a high prevalence of vat in group B2 phylogenetic 494 
strains of the ECOR collection. A high frequency of the vat gene has also been observed in B2 495 
strains associated with cystitis, pyelonephritis and prostatitis (45, 59), and vat has been strongly 496 
associated with avian pathogenic E. coli (APEC) (96). Our analysis identified the vat gene in 497 
68% of urosepsis isolates (n = 45). We also demonstrated that the sequence of vat is highly 498 
conserved within a selection of strains representative of each of the ten different sequence types 499 
identified in our collection. At the amino acid level, minor sequence variations were located 500 
within two regions (VR1: S520-K529 and VR2: E783-V823) of the Vat passenger domain. However, 501 
the canonical serine protease domain that is important for the catalytic function of SPATEs was 502 
conserved in all ten of the Vat sequences analysed. Western blotting was also performed to 503 
examine Vat expression, and revealed that Vat is expressed and secreted by all of the urosepsis 504 
strains examined when grown at human core body temperature. Further investigation is required 505 
to determine whether the minor sequence changes observed in Vat are associated with 506 
corresponding differences in its cytotoxic properties. 507 
 508 
Bioinformatic analysis identified a gene encoding a putative MarR-like transcriptional regulator 509 
immediately downstream of vat (i.e. vatX). Although mutation of vatX did not result in a 510 
detectable change in vat transcription or translation, overexpression of VatX via the introduction 511 
of a plasmid containing the vatX gene (pVatX) was shown to positively regulate vat, resulting in 512 
a 3-fold increase in vat transcription and a significant increase in the level of secreted Vat 513 
protein. This data was suggestive of a more complex regulatory control of the vat gene. We 514 
therefore mapped the promoter of vat, and identified several putative H-NS binding sites 515 
proximal to this region. H-NS is a histone-like DNA-binding protein that shows affinity for A-T 516 
rich and bent nucleation sites on DNA (97). In E. coli, H-NS has been shown to regulate multiple 517 
genes, including genes associated with virulence, pH, osmoregulation and temperature sensing 518 
(98-101). Our EMSA data revealed a strong interaction between H-NS and a 252-bp region of 519 
the vat promoter that contains three putative H-NS binding sites. A role for H-NS in vat 520 
regulation was subsequently demonstrated through the examination of a CFT073hns mutant, 521 
which secreted a significantly higher level of Vat compared to the parent CFT073 strain. Taken 522 
together, these results demonstrate that the regulation of vat is coordinated by both VatX and H-523 
NS, and further highlights the role of H-NS in the regulation of UPEC virulence factors (8, 9). 524 
 525 
The MarR family of transcriptional regulators control the expression of multiple different genes, 526 
including virulence factors, often in response to environmental stress (reviewed in 102, 103). 527 
Bioinformatic analysis of MarR-type regulators from 77 completely sequenced E. coli genomes 528 
revealed a high level of amino acid sequence conservation for proteins in each clade, but 529 
significant variation between MarR regulators from different clades. VatX clustered as a separate 530 
clade and is most closely related to PapX. Interestingly, the proteins encoding for other fimbrial 531 
associated MarR-type regulators were also found within the PapX clade (Fig S1). Despite their 532 
association with different fimbriae, these regulatory proteins are highly conserved (≥97% amino 533 
acid identity). Some strains such as E. coli 536, 83972 and Nissle 1917 possess three or more 534 
chromosomal copies of papX (Table S2). PapX regulates UPEC motility by repressing 535 
transcription of the flhDC master regulator genes (47). We investigated the potential for VatX to 536 
repress flagella-mediated motility of CFT073. However, no significant difference in motility was 537 
observed between WT CFT073, CFT073vatX and the complemented CFT073vatX (pVatX) 538 
mutant strains after growth at 28°C and 37°C (data not shown). The FliC major flagellin subunit 539 
was also produced at a similar level in all three strains as determined by immunoblotting (data 540 
not shown). Taken together, our data has identified VatX as a new member of the MarR type 541 
family that appears to regulate vat in concert with H-NS. Further work is now required to map 542 
the direct binding of VatX to the vat gene promoter, and to examine the competitive interplay 543 
between VatX and H-NS in the regulation of vat transcription.   544 
 545 
In a recent study using high-throughput transposon mutagenesis screening (50), the vat gene was 546 
shown to contribute to survival of the UPEC strain CFT073 in the bloodstream of mice. This, 547 
together with the observation that many urosepsis strains secrete Vat, prompted us to examine 548 
the immunoreactivity of Vat in urosepsis patients. We detected a significant increase in Vat-549 
specific IgG titre in the plasma of urosepsis patients infected with vat-positive UPEC strains 550 
compared to plasma from patients infected with vat-negative strains and healthy controls. 551 
Although we cannot rule out that the responses we detected may in part be due to previous or 552 
ongoing infection that culminated in sepsis, overall the data is consistent with the notion that Vat 553 
is expressed during infection and elicits a strong immune response in some patients. Further 554 
work is now required to understand the role of Vat during human infection and its cytotoxicity 555 
profile.  556 
 557 
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 868 
FIGURE LEGENDS 869 
 870 
FIG. 1. (A) BLAST alignment demonstrating the level of nucleotide sequence conservation 871 
(grey shading) for vat and vatX (labelled red), as well as the other surrounding genes (labelled 872 
blue). The Vat-PAI (defined by the proA and yagU genes [labelled yellow]) was identified in 14 873 
of 77 complete E. coli genomes examined. These sequences were compared to the Vat-PAI 874 
originally identified in the avian pathogenic E. coli strain Ec222 (top). (B) Immunodetection of 875 
the Vat passenger domain (Vatα) from supernatant fractions prepared from overnight cultures of 876 
the well-characterised UPEC strains CFT073, IHE3034 and 536. Vat expression by MG1655 877 
(pVat) is shown as a positive control, while MG1655(pSU2718) and CFT073vat were included 878 
as a negative controls.  879 
 880 
FIG. 2. Phylogram demonstrating the relationship between representative E. coli MarR-type 881 
regulator proteins. The scale represents the number of amino acid substitutions per site over 194 882 
positions. 883 
 884 
FIG. 3. (A) qRT-PCR analysis of vat transcription in CFT073vatX and CFT073vatX(pVatX) 885 
compared to wild-type CFT073. The transcription of vat was significantly increased in 886 
CFT073vatX(pVatX) compared to CFT073 (**P<0.01). (B) Western blot analysing the effect of 887 
VatX on Vat expression. Supernatant fractions were prepared from overnight cultures of 888 
MG1655(pVat), MG1655(pSU2718), CFT073(pSU2718), CFT073(pVatX), 889 
CFT073vatX(pSU2718) and CFT073vatX(pVatX). Over-expression of VatX led to an increase in 890 
the amount Vat detected in the culture supernatant.  891 
 892 
FIG. 4. (A) Schematic of the vat-vatX gene operon in CFT073. The position of the promoter and 893 
primers used to identify vat-vatX and vatX transcripts is indicated. The inset shows the vat gene 894 
transcriptional start site (+1), which was mapped to 80bp upstream of the ATG start codon (grey 895 
arrow). Also indicated are the consensus -10 and -35 promoter elements and the three putative H-896 
NS nucleation sites (shown in bold). (B) Immunodetection of the Vat passenger domain from the 897 
supernatant fractions of CFT073 , CFT073vat, CFT073vatX, CFT073hns  and CFT073vatX hns. 898 
The level of Vat was increased in CFT073hns and CFT073vatX hns compared to CFT073. (C) 899 
EMSA demonstrating the direct interaction of H-NS with the vat promoter region. The assay was 900 
performed using a 252bp fragment encompassing the vat promoter region (indicated by an 901 
asterisk), a 218bp fragment containing the bla promoter region amplified from pBR322 (positive 902 
control: indicated by an arrow), and three additional DNA fragments amplified from pBR322 903 
(negative controls: 152bp, 312bp and 479bp). Native H-NS protein was incubated with the DNA 904 
in increasing concentrations (0μM H-NS, 0.1μM H-NS, 0.5μM H-NS and 1.0μM H-NS). (D) 905 
Transcriptional analysis of the vat and vatX genes. Total RNA was extracted during exponential 906 
growth of CFT073hns and converted to cDNA. Shown are the PCR products [vat-vatX (1112bp) 907 
or vatX (404bp)] amplified from CFT073hns gDNA (positive control), total RNA (negative 908 
control) and cDNA.  909 
 910 
FIG. 5. (A) Diagram depicting the full length Vat primary protein sequence, including three 911 
protein domains typical for SPATES: i) the extended signal peptide (SP); ii) the passenger 912 
domain comprising the Immunoglobulin A1 protease-like domain, which contains the serine 913 
protease motif, as well as the upstream aspartate (D158) and histidine (H130) residues of the 914 
catalytic triad; and iii) the translocation domain, which is cleaved at the alpha-helical linker 915 
region. Class II SPATEs are characterised by the presence of a small additional domain termed 916 
Domain 2 (striped). Two variable regions (VR1 and VR2) located within the passenger domain 917 
were identified (triangles). (B) Alignment of the Vat amino acid sequence in VR1 and VR2 from 918 
CFT073 and the ten strains representing the diverse STs examined. Residues identical to those in 919 
Vat from CFT073 are indicated by dots; residues that differed from the CFT073 sequence are 920 
indicated and highlighted in grey. Vat secretion was determined by Western blot analysis of the 921 
supernatant fractions from each strain following overnight growth in LB broth at 37°C. All 922 
strains secreted a ~110kDa protein that cross-reacted with the Vat-specific polyclonal antibody 923 
(indicated as +). 924 
 925 
FIG. 6. Immunoreactivity of Vat. Blood plasma was collected from 45 urosepsis patients at the 926 
time of admittance to hospital. Paired UPEC strains were also isolated from the blood of each 927 
patient, and the presence of the vat gene was determined by PCR. Plasma samples were 928 
subsequently grouped by their association with vat-positive (Vat+) or vat-negative (Vat-) strains. 929 
The presence of IgG-specific antibodies was determined by ELISA, and compared to results 930 
obtained from 42 healthy volunteers with no recent history of UTI (Healthy). A significantly 931 
higher IgG titre was observed in plasma of patients infected with Vat+ strains compared to 932 
patients infected with Vat- strains and healthy controls. 933 
 934 
 935 






